The novel blood test uses vibrational spectroscopy and metabolomic analysis to differentiate patients with fibromyalgia from those with other autoimmune disorders.
The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.
The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.
Veracyte has obtained rights to a 52-gene signature developed by Yale researchers to predict disease progression in patients with idiopathic pulmonary fibrosis.
PharmaCyte, which develops therapies for cancer and diabetes, will be responsible for development and commercialization of tests based on the technology.
Biomerica intends to manufacture ELISA test technology licensed from Mt. Sinai. The firm said it has capacity to manufacture 1 million tests per month.
